Hematologic Oncology

The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance

The FDA has granted Fast Track Designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the potential treatment of patients with acute myeloid leukemia.

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Jorge E. Cortes, MD, has been an investigative leader for nearly 30 years in the development of numerous leukemia treatments.

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Red blood cells processed and stored in a hypoxic state maintain their integrity, which may reduce the risk of developing vaso-occlusion after red blood cell transfusion.

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Itolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem cell transplantation, and improve outcomes for these patients.